Table 2.
Distribution of different mannose binding lectin (MBL) phenotypes in clinical categories of systemic lupus erythematosus (SLE)
| Clinical categories | High MBL (n = 44) |
Intermediate MBL (n = 13) |
Low MBL (n = 36) |
P-value; odds ratio |
|---|---|---|---|---|
| Nephritis | 13 (29) | 4 (31) | 10 (28) | NS |
| Nephritis and carditis, or NPSLE, or serositis | 16 (36) | 5 (38) | 4 (11) | 0.01; 4.571 0.04; 5.002 |
| AIHA | 4 (9) | 3 (23) | 3 (8) | NS |
| Carditis | 5 (11) | 0 | 1 (3) | NS |
| NPSLE | 14 (31) | 4 (31) | 8 (22) | NS |
| Serositis | 8 (18) | 3 (23) | 7 (19) | NS |
| Musculoskeletal and cutaneous only | 2 (5) | 3 (23) | 11 (31) | 0.002; 9.421 |
1High vs. Low; 2Intermediate vs. Low; data are number (%) of participants. Based on the plasma MBL levels, SLE patients were categorised as high MBL producers (mean 2.04 μg/ml), intermediate MBL producers (mean 1.03 μg/ml), or low MBL producers (mean 0.33 μg/ml). The Fisher exact test was used to compare the distribution of MBL phenotypes in SLE manifestations. AIHA, autoimmune hemolytic anemia; NPSLE, neuropsychiatric systemic lupus erythematosus; NS, not significant.